SCHEDULE 13G/A: Janus Henderson Group Reports Zero Beneficial Ownership in Precision BioSciences
Beneficial Ownership Report
Janus Henderson Group plc has filed an amended Schedule 13G, indicating it holds no beneficial ownership in Precision BioSciences, Inc. as of December 31, 2024.
Summary
- Janus Henderson Group plc filed an Amendment No. 2 to Schedule 13G concerning its beneficial ownership of Common Stock in Precision BioSciences, Inc.
- As of December 31, 2024, Janus Henderson Group plc reports 0.00 shares beneficially owned, representing 0.0% of the class of securities.
- This filing indicates that Janus Henderson Group plc no longer holds a reportable beneficial ownership stake in Precision BioSciences, Inc.
- The reporting entity, Janus Henderson Group plc, is based in Jersey and is classified as an Investment Adviser (IA) and Parent Holding Company (HC).
- The filing certifies that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing reporting a change in beneficial ownership to 0%, which is a neutral event in itself, providing no positive or negative financial performance data for the issuer.
Future Outlook
NA
Industry Context
This filing is a standard regulatory disclosure by an institutional investor, Janus Henderson Group plc, regarding its holdings in Precision BioSciences, Inc. The reported 0.0% ownership indicates a complete divestment or a non-reportable position by this specific asset manager, which is a common occurrence in dynamic investment portfolios. It does not inherently reflect broader industry trends but rather a specific portfolio decision.
Stakeholder Impact
- Shareholders: Existing shareholders of Precision BioSciences, Inc. might note the exit of Janus Henderson Group plc as a beneficial owner, which could be interpreted differently depending on market sentiment.
- Janus Henderson Group plc: This filing reflects a change in their portfolio holdings, indicating a divestment or reduction below reporting thresholds.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date Power of Attorney was executed by Janus Henderson Group plc. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-14 | Date of signature for the Schedule 13G filing. |
Keywords
Precision BioSciences, Janus Henderson Group, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.